Premature ejaculation: the AU general practice approach

Premature ejaculation is more common, more treatable, and more often untreated than most clinicians appreciate. Surveys consistently find fewer than one in four affected men ever raise the subject with a GP — a treatment gap that general practice is well placed to close.

A. Core clinical — the AU general-practice framework

Definition and subtypes

The International Society for Sexual Medicine (ISSM) 2014 definition requires three concurrent elements: ejaculation that always or nearly always occurs within approximately one minute of penetration (lifelong subtype) or a clinically meaningful, bothersome reduction in latency to approximately three minutes or less (acquired subtype); inability to delay ejaculation on all or nearly all penetrations; and negative personal consequences — distress, frustration, or avoidance of sexual intimacy.

The four Waldinger subtypes guide management:

• Lifelong PE — present since the first sexual experience; neurobiologically driven by serotonin transporter (SLC6A4) gene polymorphisms that lower ejaculatory threshold; requires sustained pharmacotherapy and behavioural work.
• Acquired PE — develops after a period of normal ejaculatory function; a secondary cause is usually identifiable and should be treated first.
• Natural variable PE — situational, intermittent, within the normal spectrum; psycho-education and reassurance rather than diagnosis or treatment.
• Subjective PE — the patient’s perceived latency does not match objective measurement, which falls within normal range; CBT and realistic expectation-setting are the appropriate response.

History and examination

A structured history asks about onset (lifelong versus acquired), estimated intravaginal ejaculatory latency time (IELT), distress for the patient and partner, and impact on intimacy or avoidance. Screen explicitly for comorbid erectile dysfunction — present in approximately half of men with PE and requiring treatment first — as well as symptoms of hyperthyroidism (tremor, palpitations, weight loss), lower urinary tract symptoms suggesting prostatitis, recent SSRI cessation, and opioid use or withdrawal. Therapeutic Guidelines recommends assessing mood, performance anxiety, and relationship context in all presentations.

Examination covers BP and BMI, thyroid signs if clinically suspected, genital assessment for phimosis or Peyronie’s disease, and a digital rectal examination of the prostate if lower urinary tract symptoms are present.

Investigations

PE is a clinical diagnosis; investigations are targeted rather than routine per ISSM 2024:

• TSH — if hyperthyroid features present, or in any new acquired PE without another clear cause (up to half of hyperthyroid men have ejaculatory disturbance that normalises with treatment).
• Morning testosterone and SHBG — if concurrent low libido or erectile dysfunction.
• Fasting glucose and HbA1c — if erectile dysfunction coexists, to complete cardiovascular risk assessment.
• STI screen — if appropriate to the clinical context.
• Midstream urine and expressed prostatic secretions — if chronic prostatitis or CPPS features are present.

Common clinical pitfalls

Failing to elicit comorbid erectile dysfunction is the most consequential error — treating erectile dysfunction alone resolves PE in approximately half of acquired cases. Missing hyperthyroidism as a cause of new-onset PE is a second common omission. Unrealistic IELT goals are frequently set: an IELT of three to five minutes is clinically satisfactory; media-derived expectations of ten or more minutes are unhelpful and should be explicitly reframed. Not involving the partner substantially limits treatment response.

B. Evidence — what works

Behavioural techniques

Three first-line behavioural strategies have decades of trial support and are recommended by ISSM 2024 and Therapeutic Guidelines:

Stop-start technique (Semans 1956) — all stimulation pauses as ejaculation approaches, then resumes once arousal subsides. Practised alone initially, then with a partner. Consistent practice builds voluntary ejaculatory control over weeks to months.

Squeeze technique (Masters and Johnson 1970) — firm pressure applied to the coronal ridge or glans at the pre-ejaculatory moment. Mechanism and efficacy are comparable to stop-start. The two techniques can be used interchangeably.

Pelvic floor physiotherapy — a 2014 randomised controlled trial by Pastore and colleagues found 12 weeks of structured pelvic floor rehabilitation targeting the bulbocavernosus and ischiocavernosus muscles nearly tripled IELT in men with lifelong PE. This drug-free option is particularly suitable for men who prefer to avoid systemic medication or who wish to combine it with pharmacotherapy.

CBT and couples therapy — addresses performance anxiety, relationship dynamics, and catastrophic cognitions about ejaculatory control. Eligible under a Better Access Mental Health Treatment Plan for up to 10 Medicare-subsidised psychology sessions per year. A psychologist or sex therapist with sexual health training is preferred.

Pharmacotherapy

Per ISSM 2024 and eTG:

Agent	Indication	Timing	AU access
Dapoxetine 30–60 mg	Occasional or new-onset PE	1–3 hours before	TGA-approved; NOT PBS (~$50–100 per 4 tabs)
Sertraline 50–100 mg daily	Frequent or severe PE	Chronic; effect after 1–3 weeks	PBS general schedule (off-label)
Paroxetine 20 mg daily	Frequent PE; strongest IELT effect	Chronic; effect after 1–3 weeks	PBS general schedule (off-label)
Fluoxetine 20–40 mg daily	Frequent PE; longer half-life	Chronic	PBS general schedule (off-label)
EMLA cream (lidocaine 2.5% + prilocaine 2.5%)	Any PE; avoids systemic effects	Apply to glans 10–30 min prior, wash off before intercourse	OTC general schedule
Fortacin spray (lidocaine + prilocaine)	Any PE; lower partner transfer	3 sprays to glans 5 min prior	TGA-approved 2023; NOT PBS (~$80–150)
Tramadol 25–50 mg PRN	Third-line only	4–8 hours prior	PBS Authority; SafeScript-monitored

Dapoxetine is a short-acting SSRI specifically licensed for PE, with rapid onset and a half-life of approximately 1.5 hours suited to on-demand use. A McMahon 2010 randomised controlled trial showed approximately 2.5-fold IELT improvement. It is contraindicated with MAOIs, in patients with syncope history, and in severe hepatic impairment. Principal adverse effects include nausea, dizziness, and (rarely) syncope. The principal practical limitation in Australia is cost: it is not PBS-listed, making sustained use expensive for many men.

Off-label daily SSRIs exploit the ejaculation-delaying side-effect of serotonergic agents. A 2004 meta-analysis by Waldinger and colleagues showed paroxetine 20 mg daily produces the strongest IELT effect (approximately 7–8 times baseline), but sertraline 50–100 mg is preferred because of better tolerability and a less severe discontinuation syndrome. Effect takes one to three weeks to develop. Counsel patients about mood effects, the mandatory requirement for gradual taper rather than abrupt cessation, suicidality in patients younger than 25, and GI adverse effects in the first two weeks.

Topical anaesthetics (EMLA cream and Fortacin spray) reduce penile cutaneous sensitivity. EMLA must be washed off before intercourse to prevent partner vaginal or oral numbness — a condom can also reduce transfer. Fortacin spray has lower transfer risk and is TGA-approved since 2023 but remains private cost.

Combination behavioural and pharmacological therapy consistently outperforms either approach alone and is the ISSM 2024 first-line recommendation for most presentations of PE.

Tramadol is third-line only: SafeScript review is mandatory, combination with SSRIs risks serotonin syndrome, and dependence potential limits its role to refractory cases with documented failure of first-line treatments.

C. Australian operations

MBS items

Standard consultation items 23, 36, and 44 apply. Telehealth items (91790, 91891) are appropriate for PE follow-up and suit men who value discretion — the existing 12-month patient relationship requirement applies.

A Mental Health Treatment Plan (items 2715/2717) gives access to up to 10 Medicare-subsidised psychology sessions per year for anxiety, depression, or relationship strain associated with PE. Review item 2712 is applicable at six sessions.

General practice chronic disease management plan (items 965/967) applies where PE is managed as part of a broader chronic condition package — for example, alongside erectile dysfunction, type 2 diabetes, or depression.

Relevant pathology items: TSH 66716, morning testosterone cluster 66536, STI screen 73529. Specialist referral: urology or sexual health physician 105/106.

PBS prescribing notes

Dapoxetine is TGA-approved but not PBS-listed — private script only. Off-label daily SSRIs (paroxetine, sertraline, fluoxetine) can be prescribed under PBS general schedule when a co-diagnosed depression or anxiety indication is present; otherwise a private prescription is required for the PE indication. EMLA cream is OTC. Tramadol requires PBS Authority and SafeScript review.

Medico-legal considerations

Document the basis for off-label SSRI prescribing, the indication discussed with the patient, and adverse effect counselling including suicidality risk in patients younger than 25. SafeScript review is mandatory before any tramadol prescription — check for concurrent SSRIs, other opioids, and sedative-hypnotics. If dapoxetine is prescribed, document that concurrent serotonergic agents were excluded. Sensitive but explicit enquiry for domestic and intimate partner violence is appropriate when significant relationship distress is part of the history.

E. Special populations

Men with comorbid erectile dysfunction — treat erectile dysfunction first with PDE5 inhibitors. Approximately half of PE cases in this group improve or resolve without specific PE treatment once erectile function is restored, per McMahon 2005.

Men with hyperthyroidism — ejaculatory dysfunction (typically PE) affects approximately half of hyperthyroid men per Carani et al. 2005 and normalises with euthyroid status. Treat the thyroid condition before initiating PE-specific therapy.

Men younger than 25 — prescribing off-label SSRIs requires explicit, documented counselling about suicidality risk. Consider behavioural therapy under a Mental Health Treatment Plan as the primary approach before introducing pharmacotherapy.

Men with chronic prostatitis or CPPS — PE is a recognised feature of chronic pelvic pain syndrome. Urology review for concurrent management is appropriate.

Transgender and non-binary people — use language adapted to the patient’s anatomy and expressed identity. The same neurobiological and pharmacological principles apply to any penetrative anatomy, though research evidence is predominantly from cisgender male populations.

Men with opioid use disorder — opioid use delays ejaculation; opioid withdrawal causes PE. The substance use disorder is the primary treatment target.

When to escalate

Refer or escalate when:

• Suicidality or severe depression warrants urgent psychiatric review.
• Suspected hyperthyroidism requires endocrinology or general medicine input.
• PE coexists with erectile dysfunction refractory to oral PDE5 inhibitors — urology.
• Anatomical cause is suspected (Peyronie’s disease, phimosis, prostatitis with structural findings) — urology.
• Psychological complexity — severe relationship discord, trauma history, or sexual dysfunction affecting both partners — sex therapist or psychologist with sexual health training via Better Access.
• PE is refractory to combination behavioural and pharmacotherapy after two adequate trials — sexual health physician or urologist.

Consumer resources: HealthDirect — Premature ejaculation · Healthy Male · Better Health Channel · Society of Australian Sexologists.

What this article is and is not

This is general health information synthesised from current Australian clinical guidelines — Therapeutic Guidelines, the Australian Medicines Handbook, RACGP resources, and international society guidelines from ISSM 2024 and the AUA. It is not personal medical advice and does not create a doctor–patient relationship. Specific treatment decisions — including medication choices, dosing, and referral pathways — are made with your own GP and treating clinicians who know your full history.

For acute mental health support: Lifeline 13 11 14 · Beyond Blue 1300 22 4636.

---

Sources cited

1. Rowland D et al. — ISSM 2024 PE Guidelines. Sex Med Rev
2. Serefoglu EC et al. — ISSM 2014 definition of PE. J Sex Med
3. AUA / SMSNA — Disorders of Ejaculation Guideline 2020
4. Therapeutic Guidelines (eTG) — Sexual dysfunction in men
5. RACGP — AJGP men’s sexual health
6. Australian Medicines Handbook (AMH)
7. Healthy Male — Premature ejaculation
8. HealthDirect — Premature ejaculation
9. Better Health Channel
10. TGA — Dapoxetine and Fortacin product information
11. McMahon CG et al. — Dapoxetine RCT. Eur Urol 2010
12. Waldinger MD et al. — SSRI in PE meta-analysis. J Clin Psychopharmacol 2004
13. Pastore AL et al. — Pelvic floor physiotherapy in PE. Ther Adv Urol 2014
14. McMahon CG — PE with comorbid erectile dysfunction. Eur Urol 2005
15. Carani C et al. — Hyperthyroidism and ejaculatory dysfunction. JCEM 2005
16. Better Access Initiative
17. MBS Online — consultation, pathology, and specialist items